Imagine if testing a new drug on cells was like a movie instead of a still photo. Right now, cells sit in the same liquid for days, but in the human body, chemicals change every few seconds. This system acts like a smart faucet that precisely changes the liquid around cells in real-time to mimic how a real body works.
Preclinical drug testing is inefficient because standard cell cultures lack the temporal resolution (kinetics) of the human body. This leads to a 90% failure rate in clinical trials due to poor predictivity of static in vitro and animal models.
A plug-and-play peripheral system called Dypha, featuring a Fluidic Adaptor that clamps onto standard 96-well plates to provide automated, continuous fluidic control.
If you are a drug discovery firm dealing with the fact that 9 out of 10 drugs fail in human trials — this project developed the Dypha system that simulates fluctuating drug concentrations to better predict efficacy and safety.
If you are a preclinical testing lab dealing with high costs and low translation success of animal models — this project developed a plug-and-play fluidic adaptor that adds kinetic dimensions to standard 96-well plates.
If you are a personalized medicine startup dealing with simplistic 3D organoid cultures — this project developed automated fluidic control that allows for patient-relevant drug exposure levels in vitro.
Based on available project data, specific pricing or cost structures are not provided; the project is currently in the transition phase from pilot to product.
Yes, the system is designed to work with standard 96-well plates and aims to provide automated fluidic control and microscopic readout for high-throughput testing.
Based on available project data, the technology is developed by Sync Biosystems, but specific licensing terms are not disclosed in the project summary.
The system uses a Fluidic Adaptor that clamps onto standard cell culture devices, making it a plug-and-play peripheral for biologists already using standard well plates.
The project runs from 2024-04-01 to 2027-03-31, focusing on bringing the technology from pilot to product.
The consortium is heavily industry-weighted (67%), featuring 4 industrial partners and 2 SMEs. This structure, combined with the inclusion of high-profile end-users like Charles River Laboratories and specialized pediatric hospitals, indicates a strong focus on commercial validation and market-fit rather than basic research.
Contact DEMCON SYNC BIOSYSTEMS BV in the Netherlands
Contact us to explore licensing opportunities for kinetic cell culture automation.
